ArticleRadiology2018
An Intravascular Tantalum Oxide-based CT Contrast Agent: Preclinical Evaluation Emulating Overweight and Obese Patient Size.
Article in Radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- Photopolymerized radiopaque composites for long-term imaging in transcatheter arterial embolization.RSC advances · 2026Article
- Nanomaterials reshaping cancer radiotherapy: Radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies.Materials today. Bio · 2026Review
- Material Composition and Implantation Site Affect in vivo Device Degradation Rate.Research square · 2026Article
- Gram-Scale Synthesis of Hafnium-Rich Carbon Dots for Preclinical Computed Tomography Imaging Across Various Systems.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An in silico evaluation of signal and separability properties of k-edge materials in spectral CT.Scientific reports · 2026Article
- Metal artifact reduction and contrast agent performance as a function of source spectral shape.Physics in medicine and biology · 2025Article
- Review
- Toward the clinical translation of safe intravenous long circulating ILNEs contrast agent for CT imaging.Theranostics · 2025Article
- Insights into nanoparticle surface bonding and coating architecture via multinuclear NMR.Academia nano : science, materials, technology · 2025Article
- Nanomedicine: The new trend and future of precision medicine for inflammatory bowel disease.Chinese medical journal · 2024Review
- Computed tomography technologies to measure key structural features of polymeric biomedical implants from bench to bedside.Journal of biomedical materials research. Part A · 2024Article
- Advancements in tantalum based nanoparticles for integrated imaging and photothermal therapy in cancer management.RSC advances · 2024Review
- Novel intravascular tantalum oxide-based contrast agent achieves improved vascular contrast enhancement and conspicuity compared to Iopamidol in an animal multiphase CT protocol.European radiology experimental · 2024Article
- An Investigation on the Effect of Contrast Agents in the Chitosan-Nanoclay Shear Thinning Hydrogel for Trans-Catheter Arterial Embolization.JOM (Warrendale, Pa. : 1989) · 2024Article
- Material Composition and Implantation Site Affect in vivo Device Degradation Rate.bioRxiv : the preprint server for biology · 2024Article
- Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy.Pharmaceutics · 2024Review
- Fusing Positive and Negative CT Contrast Nanoagent for the Sensitive Detection of Hepatoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Clinical Applications of Photon-counting CT: A Review of Pioneer Studies and a Glimpse into the Future.Radiology · 2023Review
- Incorporating Tantalum Oxide Nanoparticles into Implantable Polymeric Biomedical Devices for Radiological Monitoring.Advanced healthcare materials · 2023Article
- Evaluating Hydroxyapatite, Gold Nanoparticles, and Graphene-Copper as Bimodal Agents for X-ray and Computed Tomography.Bioengineering (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Purpose To compare the CT imaging performance of a carboxybetaine zwitterionic-coated tantalum oxide (TaCZ) nanoparticle CT contrast agent with that of a conventional iodinated contrast agent in a swine model meant to simulate overweight and obese patients. Materials and Methods Four swine were evaluated inside three different-sized adipose-equivalent encasements emulating abdominal girths of 102, 119, and 137 cm. Imaging was performed with a 64-detector row CT scanner at six scan delays after intravenous injection of 240 mg element (Ta or I) per kilogram of body weight of TaCZ or iopromide. For each time point, contrast enhancement of the aorta and liver were measured by using regions of interest. Two readers independently recorded the clarity of vasculature using a five-point Likert scale. Findings were compared by using paired t tests and Wilcoxon signed-rank tests. Results Mean peak enhancement was higher for TaCZ than for iopromide in the aorta (270 HU [σ = 24.5] vs 199 HU [σ = 10.2], P < .001) and liver (61.3 HU [σ = 11.7] vs 45.2 HU [σ = 8], P < .001). Vascular clarity was higher for TaCZ than for iopromide in 63% (132 of 208), 82% (170 of 208), and 86% (178 of 208) of the individual vessels at the 102-, 119-, and 137-cm girths, respectively (P < .01). Arterial clarity scores were higher for TaCZ than for iopromide in 62% (208 of 336) of vessels. Venous clarity scores were higher for TaCZ than for iopromide in 89% (128 of 144) of the veins in the venous phase and in 100% (144 of 144) of veins in the delayed phase (P < .01). No vessel showed higher clarity score with iopromide than with TaCZ. Conclusion An experimental tantalum nanoparticle-based contrast agent showed greater contrast enhancement compared with iopromide in swine models meant to simulate overweight and obese patients. © RSNA, 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.